Kynurenic acid protects against the homocysteine-induced impairment of endothelial cells

Pharmacological Reports

Volumn 61, Issue 4, 2009, Pages 751-756

  Wejksza, Katarzyna ^a   Rzeski, Wojciech ^a,b   Turski, Waldemar A ^b,c  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Endothelial cells; Homocysteine; Kynurenic acid

Indexed keywords

BUNGAROTOXIN RECEPTOR; GLUTAMATE RECEPTOR; HOMOCYSTEINE; KYNURENIC ACID; KYNURENINE; TRYPTOPHAN;

ANIMAL CELL; ANTICONVULSANT ACTIVITY; AORTA; ARTICLE; BRAIN TISSUE; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; COW; CYTOTOXICITY; ENDOTHELIUM; ENDOTHELIUM CELL; HYPERHOMOCYSTEINEMIA; NONHUMAN;

EID: 70549088032     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70130-6     Document Type: Article

References (27)

1. Birch PJ, Grossman CJ, Hayes AG: Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol, 1988, 154, 85-87.
2. Bleich S, Junemann A, von Achsen N, Lausen B, Ritter K, Beck G, Naumann GO, Kornhuber J: Homocysteine and risk of open-angle glaucoma. J Neural Transm, 2002, 109, 1499-1504.
3. Fukushima T, Mitsuhashi S, Tomiya M, Iyo M, Hashimoto K, Toyo'oka T: Determination of kynurenic acid in human serum and its correlation with the concentration of certain amino acids. Clin Chim Acta, 2007, 377, 174-178.
4. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX: The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J Neurosci, 2001, 21, 7463-7473. (Pubitemid 32904945)
5. Lee SJ, Kim KM, Namkoong S, Kim CK, Kang YC, Lee H, Ha KS et al.: Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine. J Biol Chem, 2005, 280, 5781-5788. (Pubitemid 40280058)
6. Milart P, Sikorski R: Kynurenic acid concentration in blood and urine during normal pregnancy (Polish). Ginekol Pol, 1998, 69, 968-973.
7. Nagai Y, Tasaki H, Takatsu H, Nihei S, Yamashita K, Toyokawa T, Nakashima Y: Homocysteine inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun, 2001, 281, 726-731. (Pubitemid 32917861)
8. Parada-Turska J, Rzeski W, Zgrajka W, Majdan M, Kandefer-Szerszeń M, Turski W: Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro. Rheumatol Int, 2006, 26, 422-426. (Pubitemid 43318322)
9. Potter K: Homocysteine and cardiovascular disease: should we treat? Clin Biochem Rev, 2008, 29, 27-30.
10. Rejdak R, Żarnowski T, Turski WA, Okuno E, Kocki T, Zagórski Z, Kohler K et al.: Presence of kynurenic acid and kynurenine aminotransferases in the inner retina. Neuroreport, 2001, 12, 3675-3678. (Pubitemid 33105149)
11. Rzeski W, Matysiak J, Kandefer-Szerszeń M: Anticancer, neuroprotective activities and computational studies of 2-amino-1,3,4- thiadiazole based compound. Bioorg Med Chem, 2007, 15, 3201-3207.
12. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med, 2002, 346, 476-483. (Pubitemid 34441738)
13. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA, 1992, 268, 877-881.
14. Stazka J, Luchowski P, Urbanska EM: Homocysteine, a risk factor for atherosclerosis, biphasically changes the endothelial production of kynurenic acid. Eur J Pharmacol, 2005, 517, 217-223. (Pubitemid 40977898)
15. Suhara T, Fukuo K, Yasuda O, Tsubakimoto M, Takemura Y, Kawamoto H, Yokoi T et al.: Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways. Hypertension, 2004, 43, 1208-1213.
16. Swartz KJ, Matson WR, MacGarvey U, Ryan EA, Beal MF: Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. Anal Biochem, 1990, 185, 363-376. (Pubitemid 20107178)
17. Turski MP, Turska M, Zgrajka W, Kuc D, Turski WA: Presence of kynurenic acid in food and honeybee products. Amino Acids, 2009, 36, 75-80.
18. Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO, Jr Schwarcz R: Identification and quantification of kynurenic acid in human brain tissue. Brain Res, 1988, 454, 164-169. (Pubitemid 18159785)
19. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, Loscalzo J: Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem, 1997, 272, 17012-17017.
20. Urbańska EM, Luchowski P, Luchowska E, Pniewski J, Woźniak R, Chodakowska-Żebrowska M, Łazarewicz J: Serum kynurenic acid positively correlates with cardiovascular disease risk factor, homocysteine: a study in stroke patients. Pharmacol Rep, 2006, 58, 507-511. (Pubitemid 44383275)
21. Van den Berg M, Boers GH, Franken DG, Blom HJ, Van Kamp GJ., Jakobs C, Rauwerda JA et al.: Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest, 1995, 25, 176-181.
22. Virdis A, Iglarz M, Neves MF, Amiri F, Touyz RM, Rozen R, Schiffrin EL: Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. Arterioscler Thromb Vasc Biol, 2003, 23, 1352-1357. (Pubitemid 36994521)
23. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L: Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem, 2006, 281, 22021-22028. (Pubitemid 44181906)
24. Weiss N: Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab, 2005, 6, 27-36.
25. Wejksza K, Rzeski W, Parada-Turska J, Zdzisinska B, Rejdak R, Kocki T, Okuno E et al.: Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor. Naunyn Schmiedebergs Arch Pharmacol, 2004, 369, 300-304.
26. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med, 1998, 338, 1042-1050.
27. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, Kitajima S: Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem, 2001, 276, 35867-35874. (Pubitemid 37384393)